Aspen Pharmacare PE Ratio 2017-2025 | APNHY
Current and historical p/e ratio for Aspen Pharmacare (APNHY) from 2017 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Aspen Pharmacare PE ratio as of September 17, 2026 is 0.00.
| Aspen Pharmacare PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2026-09-16 | 9.52 | 0.00 | |
| 2025-12-31 | 7.05 | 0 | 0.00 |
| 2025-06-30 | 6.58 | 0 | 0.00 |
| 2024-12-31 | 8.55 | 0 | 0.00 |
| 2024-06-30 | 12.27 | 0 | 0.00 |
| 2023-12-31 | 10.69 | 0 | 0.00 |
| 2023-06-30 | 9.15 | 0 | 0.00 |
| 2022-12-31 | 7.54 | 0 | 0.00 |
| 2022-06-30 | 7.80 | 0 | 0.00 |
| 2021-12-31 | 12.93 | 0 | 0.00 |
| 2021-06-30 | 10.32 | 0 | 0.00 |
| 2020-12-31 | 7.76 | 0 | 0.00 |
| 2020-06-30 | 7.51 | 0 | 0.00 |
| 2019-06-30 | 6.47 | 0 | 0.00 |
| 2018-12-31 | 8.52 | 0 | 0.00 |
| 2018-06-30 | 16.80 | 0 | 0.00 |
| 2017-12-31 | 19.98 | 0 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $4.248B | $2.065B |
| Aspen Pharmacare Holdings Limited provide specialty, branded and generic pharmaceuticals for acute and chronic conditions. It operates primarily in Sub-Saharan Africa, Latin America, South East Asia and Eastern Europe. Aspen Pharmacare Holdings Limited is headquartered in Durban, South Africa. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |